Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose.
Ian Douglas PavordArnaud BourdinAlberto PapiChristian Domingo RibasJonathan CorrenArman AltincatalAmr RadwanNami PanditJuby Anne Jacob-NaraYamo DenizPaul J RoweElizabeth LawsDavid J LedererMegan HardinPublished in: Allergy (2023)
Dupilumab showed sustained efficacy for up to 3 years in patients with uncontrolled, moderate-to-severe type 2 asthma on high- or medium-dose ICS.